Onderzoeksklasse Varlilumab

Varlilumabisafullyhumanmonoclonalantibody (mAb) thattargetsCD27, acriticalmoleculeintheactivationpathwayoflymphocytes.LikeCD40, CD27canbeeffectivelymanipulatedwithactivatingantibodiestoinducepotentanti-tumorresponses, andmayresultinlesstoxicitiesduetoitsrestrictedexpressionandregulation.Varlilumabisanovel, first-in-class, agonistCD27antibodythatstimulatestheCD27pathway, whichresultsinT-cellactivationandantitumoractivityintumormodels.Thisfirst-in-human, dose-escalationandexpansionstudyevaluatedthesafety, pharmacology, andactivityofvarlilumabinpatientswithadvancedsolidtumors.

1F5, CDX-1127, CAS:1393344-72-3

Mammalian Cells

CD27Lreceptor, TNFRSF7, T14, CD27antigen, Tumornecrosisfactorreceptorsuperfamilymember7, CD27, T-cellactivationantigenCD27

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

2mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -188°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-kappa